Precision Chroma Raises $7.3M Seed Led by M Ventures

Precision Chroma Closes $7.3M Seed Round

Precision Chroma, a University of Canterbury spin-out based in Christchurch, New Zealand, has raised a $7.3 million seed round led by M Ventures. The round also includes participation from Icehouse Ventures, Bridgewest Ventures and New Zealand Growth Capital Partners.

What the Company Does

Launched in January 2022, Precision Chroma manufactures patented 3D-printed chromatography columns built on its Printed Monolith Adsorption (PMA) technology. These columns are used to purify biological medicines, including:

• Proteins
• Antibodies
• Vaccines
• Gene therapies

The company positions its columns as a replacement for traditional packed-particle systems, reducing processing steps, time and cost in biopharmaceutical manufacturing.

Origins and Backing

Precision Chroma was spun out of the University of Canterbury and incubated by Bridgewest Ventures. It is part of Callaghan Innovation's Technology Incubator Programme and operates across New Zealand and in Miami.

Deal Summary

• Company: Precision Chroma
• Round: Seed
• Amount: $7.3 million USD
• Lead Investor: M Ventures
• Participating Investors: Icehouse Ventures, Bridgewest Ventures, New Zealand Growth Capital Partners
• Headquarters: Christchurch, New Zealand
• Sector: Bioprocessing / biopharmaceutical manufacturing technology

Why It Matters

Downstream purification is one of the most expensive and time-intensive stages in biologic drug manufacturing. A column technology that credibly reduces processing steps and cycle time addresses a cost line that scales directly with production volume — which is why strategic and financial investors have shown interest in bioprocessing innovation.

The presence of M Ventures as lead is notable given the fund's life-sciences focus, and the round brings together a mix of local New Zealand institutional capital (Icehouse Ventures, New Zealand Growth Capital Partners) alongside the incubator that supported the company from its earliest days (Bridgewest Ventures).

Commercial Footprint

With operations spanning New Zealand and Miami, Precision Chroma is bridging a deep-tech research base in Christchurch with a presence in a major U.S. biotech corridor — a structure that supports both continued R&D and engagement with biopharmaceutical customers.

What to Watch

• Scale-up of manufacturing for the 3D-printed column line
• Commercial adoption among biopharmaceutical manufacturers
• Expansion of the Miami operations as a customer-facing base

All figures and details above are as reported in the funding announcement.